580 related articles for article (PubMed ID: 36221983)
1. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
Cheng L; Xu L; Xu Y; Yuan F; Li J; Wu M; Da Z; Wei H; Zhou L; Yin S; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Liu H; Ren T; Zang Y
Clin Rheumatol; 2024 Jan; 43(1):339-347. PubMed ID: 37985533
[TBL] [Abstract][Full Text] [Related]
3. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
4. MDA5 expression is associated with TGF-β-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis.
Shen N; Zhou X; Jin X; Lu C; Hu X; Zhang Y; Jiang Y; Xu Q; Xu X; Liu M; Lu L; Han Y
Rheumatology (Oxford); 2022 Dec; 62(1):373-383. PubMed ID: 35412608
[TBL] [Abstract][Full Text] [Related]
5. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
[TBL] [Abstract][Full Text] [Related]
6. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
7. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients.
Hensgens MPM; Delemarre EM; Drylewicz J; Voortman M; Krol RM; Dalm VASH; Miedema JR; Wiertz I; Grutters J; Limper M; Nierkens S; Leavis HL
Rheumatology (Oxford); 2022 Oct; 61(10):4087-4096. PubMed ID: 35048953
[TBL] [Abstract][Full Text] [Related]
9. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis].
Han YY; Jiang T; Zhang ZH; Li W; Jiang YD; Lu CC; Fei Y; Chen B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):422-425. PubMed ID: 36949709
[TBL] [Abstract][Full Text] [Related]
10. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
12. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
13. Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease.
Li L; Wang Q; Wen X; Liu C; Wu C; Yang F; Zeng X; Li Y
Oncotarget; 2017 Sep; 8(44):76129-76140. PubMed ID: 29100298
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
15. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis.
Shimizu T; Koga T; Furukawa K; Horai Y; Fujikawa K; Okada A; Okamoto M; Endo Y; Tsuji S; Takatani A; Umeda M; Fukui S; Sumiyoshi R; Kawashiri SY; Iwamoto N; Igawa T; Ichinose K; Tamai M; Sakamoto N; Nakamura H; Origuchi T; Mukae H; Kuwana M; Kawakami A
J Intern Med; 2021 Feb; 289(2):206-220. PubMed ID: 32691471
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China.
You H; Wang L; Wang J; Lv C; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
Rheumatology (Oxford); 2023 Mar; 62(3):1216-1226. PubMed ID: 35961045
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
19. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.
Guo L; Zhang X; Pu W; Zhao J; Wang K; Zhang D; Hong S; Ma Y; Wang X; Ye S; Guo Q; Wang J
Rheumatology (Oxford); 2023 Jun; 62(6):2320-2324. PubMed ID: 36637178
[TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
